Phase 1 Eczema Trial, Recruiting NCT07604324 Sponsor: Novartis Pharmaceuticals Condition: Eczema
Back to Eczema

Phase 1 Eczema Trial, Recruiting

NCT07604324
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Part 1 – Healthy participants:

  • Men and women aged 18 to 55 who are in good general health and have no childbearing potential

Part 2 – Participants with atopic dermatitis (eczema):

  • Men and women aged 18 or older who are not pregnant
  • People who have had a diagnosis of atopic dermatitis for at least one year that has not been well controlled with creams or ointments
  • People whose atopic dermatitis is rated as moderate to severe based on specific scoring measures assessed at both a screening visit and a baseline visit (confirm with trial site)
  • People whose eczema covers at least 10% of their body surface area at both the screening and baseline visits
  • People who report significant itch, based on daily ratings recorded in the week before the baseline visit

Who may not be able to join:

  • People who have taken part in another clinical trial or used another experimental drug within the past 30 days (or longer, depending on the drug)
  • People who are currently taking certain medications that are not permitted under the study rules (confirm with trial site)
  • People who test positive for syphilis during the screening period
  • People who show signs of active or latent tuberculosis (TB) based on a blood test during screening
  • People with a history of immune system disorders, or who test positive for HIV
  • People who have had a parasitic worm (helminth) infection in the past six months or currently have one
  • People with a history of hepatitis B or hepatitis C, or who test positive for certain hepatitis B or hepatitis C markers during screening (some exceptions may apply for hepatitis B — confirm with trial site)
  • Women who are able to become pregnant (Part 1 healthy participants only)
  • People who smoke (Part 1 healthy participants only)
  • People with atopic dermatitis who regularly use tanning beds (more than twice a week) or have had extended sun exposure within four weeks before the baseline visit
  • People with atopic dermatitis who have an ongoing uncontrolled medical condition — such as uncontrolled diabetes, high blood pressure, severe obesity, thyroid, heart, lung, liver, kidney, nerve, or mental health conditions — that could put them at increased risk during the study, as judged by the treating doctor
  • Women who are able to become pregnant (Part 2) unless a highly effective form of contraception is being used during the study and for a set period after the study treatment ends (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +81337978748

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Registry
ClinicalTrials.gov
Start date
2 June 2026
Est. completion
27 January 2028

Where this trial is recruiting

🇯🇵 Japan

Primary endpoints

Part 1-Incidence of adverse events (AEs) and serious adverse events (SAEs); Part 2-Incidence of adverse events (AEs) and serious adverse events (SAEs)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov